Compared to chemical drugs, the quality control of herbal medicinal products poses many problems due to the complexity of herbal drugs, herbal drug preparations and the products themselves, and due to the use of different analytical methods (selective and non-selective) giving different results. To illustrate this, three groups of herbal medicinal products were assayed by different analytical methods: products containing St.John's wort (colorimetry and HPLC), milk thistle (spectrophotometry and HPLC) and ginkgo (HPLC). These studies show that complete and correct labeling is necessary for the evaluation of herbal medicinal products and that for the majority of plants the knowledge of the applied analytical method is essential for a proper verification of conformity.
The mission of the Belgian Medicines Control Laboratory is the post-market quality control of medicines delivered in public pharmacies, thus also including herbal medicinal products. Compared with "chemical" drugs, the analysis of herbal medicinal products poses many problems.
First, a plant can be used in different forms: different parts of the plant (for example, leaf, flower, herb); the crude drug itself or different kind of preparations: standardized, quantified, purified or other type of preparation. In case of standardization/quantification this can be performed for either a single constituent or to a group of metabolites. As a consequence of this multiplicity of possibilities, an accurate and detailed label is necessary otherwise it is not possible to verify the product for its conformity. The following information should be stated: Latin name and part of the plant, the ratio of the herbal drug to the herbal drug preparation (DER), the extraction solvent, the physical state, and quantity of the extract. The quantity may also be given as a range corresponding to a defined quantity of constituents with known therapeutic activity [1] . Herbal medicinal products can be on the market as registered medicines or as food supplements, each with their own legal requirements. Finally, the assay of the constituent(s) can give different results depending on the applied method: a non-selective method (spectrophotometry, titrimetry) versus a selective, chromatographic method (HPLC, GC). These problems and differences are illustrated by the evaluation of three groups of herbal medicinal products containing dry extracts of Hyperici herba, Silybi mariani fructus and Ginkgonis folium.
Hyperici herba or St.John's wort consists of the whole or cut, dried flowering tops of Hypericum perforatum L., harvested during flowering time, containing not less than 0.08% of total hypericins [2] . The most characteristic constituents are naphthodianthrones, consisting mainly of hypericin and pseudohypericin. Other naphthodianthrones present, and included in the term 'total hypericin', are the biosynthetic precursors protohypericin and protopseudohypericin (which are transformed into hypericin and pseudohypericin, respectively on exposure to light), and a small amount of cyclopseudohypericin. Other constituents include phloroglucinols and flavonoids. St. John's wort is indicated for mild to moderate depressive episodes in daily dosages of 450 to 1050 mg of hydroalcoholic dry extract (with defined DER) [3] . Eight St. John's wort preparations (tablets, coated tablets or capsules) were analyzed by assaying total hypericins by spectrophotometry [2] and HPLC [4] . None of the products had a comprehensive label, the most common missing information being part of the plant, type of extract, solvent, DER and even the quantity of the extract (5 products). Five products were quantified to a defined content of hypericin, two to total hypericin and one to hypericinum (?). One product gave a minimum content of hypericin.
The assay results are summarized in Table 1 : the total hypericin content varied from 26.7% to 176.5% of their label claim for the spectrophotometric assay and from 13.3% to 84.7% for the HPLC method. The ratio of the spectrophotometric assay to the HPLC assay ranged from 2.1 to 5.4, which is in accordance with the results of the group of Prof. Vincieri and of Dr Gaedke, who obtained for commercial dry extracts ratios of 1.2 to 10 and 1.1 to 1.6, respectively [5, 6] . None of the products complied with its label claim neither for the spectrophotometric result nor for the HPLC result, taking 90.0%-110.0% of the stated amount as requirement.
Silybi mariani fructus (Cardui mariae fructus) or milk thistle fruit is the mature fruit, devoid of the pappus, of Silybum marianum (L.) Gaertner, containing a minimum of 1.5% of silymarin, expressed as silibinin. Milk thistle refined and standardized dry extract contains 30 to 65% of silymarin (determination by HPLC). The content of silymarin corresponds to 20-45% silicristin and silidianin, 40-65% silibinin A and B, and 10-20% isosilibinin A and B, with reference to total silymarin [7] . The active constituents are flavanolignans, collectively named silymarin, and consisting mainly of silibinin and isosilibinin. The milk thistle dry extract, which is the most frequently used in the pharmacological/ [8] .
Four milk thistle preparations, all formulated as capsules, were evaluated by determination of the silymarin content by spectrophotometry [9] and HPLC [7] . Three products contained a dry extract standardised to different amounts of silymarin; one product contained pure silibinin.
The results are summarized in Table 2 : for the silibinin product, 101.1% of the label claim was found by HPLC, for the other products the silymarin content varied from 82.6% to 184.9% of their label claim for the colorimetric assay and from 57.8% to 163.1% for the HPLC method. The ratio of the HPLC assay result to the colorimetric assay result ranged from 0.7 to 0.9, which is in agreement with the results of Ihrig [9] , where the same ratio range was obtained. Products 1 and 3 complied with their label claim taking the content from the colorimetric analysis and the HPLC analysis, respectively. Despite the fact that products 2 and 4 are food supplements, they contain silymarin in either the same or higher amount as the medicinal product 1.
Ginkgonis folium or ginkgo leaf is the whole or fragmented, dried leaf of Ginkgo biloba L., containing not less than 0.5% of flavonoids, calculated as flavone glycosides. Ginkgo refined and quantified dry extract contains 22.0-27. Ginkgo is indicated for mild to moderate dementia syndromes including primary degenerative dementia, vascular dementia and mixed forms; cerebral insufficiency; neurosensory disturbances such as dizziness, vertigo and tinnitus; enhancement of cognitive performance; and peripheral arterial occlusive disease (intermittent claudication). All these indications are supported by clinical trials performed with preparations based on standardized extracts, containing 22-27% flavonol glycosides and 5-7% terpene lactones. The daily dose for these preparations is 120-240 mg of standardized ginkgo dry extract, corresponding to 29-58 mg flavonoids and 7.2-14.4 mg terpene lactones [11] .
A total of 14 products, formulated as capsules and tablets, were included in the study (see Table 3 ). They all claim to contain ginkgo dry extract, ranging from 30 to 200 mg per unit. For ginkgo, the problem of different existing assay methods is not a point because in most cases the flavonoids are determined with HPLC-UV and the terpene lactones with HPLC-RI [12] . The content of total flavonoids was determined after hydrolysis to the flavonol aglycones quercetin, kaempferol and isorhamnetin. Eleven of the 14 products had a claim for flavonoid content ranging from 9.6 mg up to 36 mg per unit. For these products, between 95% and 123% of the theoretical amount was found. For the 3 other products without indication of flavonoid amount, the content varied between 8 mg and 44.5 mg total flavonoids per unit. Generally the ratio of the 3 aglycones quercetin, kaempferol and isorhamnetin in ginkgo is 5:5:1, corresponding to a relative rutin content of 10 to 15%. Because it is known that rutin is sometimes added to ginkgo extracts, a direct assay of rutin was also performed [12] . Absolute and relative contents (with reference to total flavonoids) ranged from 0.4 to 8.9 mg/unit and from 5 to 51%, respectively. Products 4-7, 11, 13 and 14 had a relative rutin content ranging from 24% to 51%, indicating a possible falsification with rutin.
Concerning the analysis of terpene lactones, for products 1-8 having a label claim, the assayed amount varied from 80% (product 4) up to 194% (product 8) of the theoretical amount. Products 9-14 (without a claim) had a content of terpene lactones between 1.42 and 4.83 mg per unit.
Only the medicinal products 1-3 complied with all the requirements: the content of total flavonoids and terpene lactones were in accordance with the stated amounts; the relative rutin content was between 10 and 15% of the total flavonoid content and their label was complete and correct. Again, for most of the food supplements the content and the corresponding daily dose of flavonoids and terpene lactones was higher when compared with the medicinal products: product 9 had no label claim, but its daily dose for flavonoids and terpene lactones corresponded respectively to about 460% and 200% of a normal daily dose. These studies show that a complete and correct label is necessary for the evaluation of herbal medicinal products. In addition, for the majority of plants, the knowledge of the applied analytical method is essential to enable a proper verification of the conformity. 100%A/0%B to 0%A/100%B in 28 min and continuing this for 8 min). The injection volume was 10 µL and UV detection was at 280 nm. Total flavonoid assay utilized a Waters Symmetry C18 150 x 4.6 mm, 5 µm column held at 25°C in combination with a gradient at 1.0 mL/min. using 2 solvents (A = 0.3 g/L of H 3 PO 4 in water adjusted to pH 2.0; B = methanol; 60%A/40%B to 45%A/55%B in 20 min.). The injection volume was 10 µL and UV detection was at 370 nm. Rutin assay was carried out on a Varian Polaris C18 250 x 4.6 mm 5 µm column at ambient temperature using a mixture of 3 g/L of H 3 PO 4 in water and acetonitrile (82:18) as mobile phase, at a flow rate of 1 mL/min, injection volume of 10 µL and UV detection at 357 nm. Terpene lactone assay: the mobile phase, a mixture of watermethanol-tetrahydrofuran (75-20-10) was pumped at 1.0 mL/min through a Waters Symmetry C8 250 x 4.6 mm, 5 µm column at 35°C, followed by a refractometer, also at 35°C. The injection volume was 100 µL.
Quantitative determination:
The samples were prepared as described in the cited references. Each determination was performed in triplicate except the terpene lactone HPLC assay, which was undertaken in duplicate. The contents are presented as a mean of data obtained from the spectrophotometric and HPLC analyses.
